Page 115 - CIBEREHD2016-ENG

Most relevant scientific articles
• Ratziu V., Harrison S.A., Francque S., Bedossa P., Lehert P., Serfaty L. et al. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. Gastroenterology. 2016;150(5):1147-1159e5.
• Eslam M., Mangia A., Berg T., Chan H.L.Y., Irving W.L., Dore G.J. et al. Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes. Hepatology. 2016;64(1):34-46.
• Vilar-Gomez E, Yasells-Garcia A, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B et al. Development and validation of a noninvasive prediction model for nonalcoholic steatohepatitis resolution after lifestyle intervention.Hepatology (Baltimore, Md.). 2016.
• Medina-Caliz I., Robles-Diaz M., Garcia-Munoz B., Stephens C., Ortega-Alonso A., Garcia-Cortes M. et al. Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury. Journal of Hepatology. 2016.
• Vilar-Gomez E., Adams L.A. Pioglitazone: An addition to our toolbox for patients with diabetes and nonalcoholic steatohepatitis?Annals of Internal Medicine. 2016;165(5):373-374.
Hightlights
The group have been granted various projects, such as: “Transición esteatohepatitis no alcohólica- hepatocarcinoma: biomarcadores y dianas terapéuticas” by Instituto Carlos III (PI16-01842), or “Uso de terápia epigenética avanzada para el tratamiento de la enfermedad hepática por deposito de grasa no alcohólica” by the Consejería de Salud de la Junta de Andalucía (PC-0148-2016-0148). It has been also awarded a prize from the Asociación de Celíacos y Sensibles al Gluten for “Estudio epigenético de la enfermedad celíaca. Nuevos métodos de diagnóstico y de seguimiento de la dieta sin gluten”. Regarding HCV, we have studied the different steps in the viral life cycle and the role that quercetin has on it. Our colaboration in the International Liver Disease Genetics Consortium have allowed to identify several genetic factors associated to progression, and to stablish an algorithm for stratifying fibrosis. The cardiovascular risk on HCV patients is also being studied (HepCar), which preliminar results had been already presented.
In the study of NAFLD, a new model for predicting reversion after life-style modification has been developed. We have validated imaging biomarkers (DEMILI®) and the use of PPAR agonists as a new therapy. Epigenetics biomarkers (miRNAs) have been identified and are under valitation.
Another epigenetic factor, lncRNA-H19, was found upregulated in liver cancer, and its role in the pathophisiology of the disease is being studied. We have also developed a non-invasive model for predicting HCC development.
Concerning hepatic encephalopathy, we have associated the critical flicker frequency with disease progression and accidental falls. The oral glutamine challenge has been related to the risk of overt hepatic encephalopathy. Finally, a large scale genetic studio was performed for detecting predictive genetic factors of the disease.
EHD
research Groups 115